Seqirus first-to-market with US 2019/20 flu vaccines

15 July 2019

Seqirus, a global leader in influenza prevention and part of Australia’s CSL Limited (ASX: CSL), announced today it is first-to-market with shipping its portfolio of seasonal influenza vaccines to customers in the USA for the 2019/20 influenza season.

Seqirus expects to distribute over 50 million doses to the US market this year, with the majority of doses coming from its adjuvanted and cell-based technology platforms.

The company will provide Fluad, the first-and-only adjuvanted seasonal influenza vaccine developed for people aged 65 and older, and Flucelvax Quadrivalent, the most widely available cell-based influenza vaccine in the country, available for those aged four and older.5

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK